RBC Capital Markets increased its price target for Viridian Therapeutics to $41 from $38, while maintaining an 'Outperform' rating. This analyst action, following the company's Q3 2026 earnings, suggests a positive outlook from RBC, though they noted speculative risk.
RBC Capital Markets has raised its price target for Viridian Therapeutics (VRDN) to $41 from $38, while reiterating its 'Outperform' rating. This upgrade follows the company's third-quarter 2026 earnings report, indicating that RBC sees continued upside potential for the stock. While generally positive, the analyst also noted the presence of 'speculative risk,' which is common in the biotechnology sector. For traders, this could signal short-term positive momentum for VRDN, as analyst upgrades often influence investor sentiment. The long-term implications depend on Viridian's continued execution and pipeline development, but the increased price target suggests a more favorable outlook from a key financial institution.